7 Aug 2019 07:00
7 August 2019
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Grant of further European patent covering composition of SFX-01
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the grant of further intellectual property rights in Europe pertaining to the novel composition, SFX-01.
The newly granted patent leads with a product claim covering "a composition comprising a complex of sulforaphane and alpha-cyclodextrin". Composition-of-matter patents have already been granted in the USA and other territories. Furthermore, patents in Europe, the US and other territories relating to the method of production have also been granted.
Details of the European patent announced today, numbered EP3354267 and entitled Stablilized Sulforaphane, can be viewed at this link:
https://register.epo.org/application?number=EP18162130&lng=en&tab=doclist
Exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.
Steve Franklin, CEO of Evgen Pharma, said: ''We are delighted by the grant of this important patent in Europe. This patent has broad claims relating to the composition of the novel drug substance, SFX-01, and as such represents a material development for the Company. It further expands the strength and depth of our intellectual property position across all the key territories with regard to the composition of the product and method of manufacture. The overall intellectual property position around SFX-01 and novel analogues has matured into an impressive patent estate, asserting our exclusive position around this new class of pharmaceutical."
Enquiries:
Evgen Pharma plc www.evgen.com | via Walbrook | |
Dr Stephen Franklin, CEO | ||
Richard Moulson, CFO | ||
finnCap www.finncap.com | +44 (0) 20 7220 0500 | |
Geoff Nash / Teddy Whiley (Corporate Finance) | ||
Alice Lane, Manasa Patil (ECM) | ||
WG Partners LLP | +44 (0) 20 3705 9330 | |
Nigel Barnes / Claes Spång | ||
Walbrook PR | +44 (0)20 7933 87870 or evgen@walbrookpr.com | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com